1. U.S. National Center for Health Statistics: http://www.cdc.gov/nchs/fastats/alzheimr.htm

2. Kiss B, et al. Mechanism of action of vinpocetine. Acta Pharm Hung. Sep1996;66(5):213-24.

3. Burtsev EM, et al. 10-year experience with using Cavinton in cerebrovascular disorders. Zh Nevropatol Psikhiatr Im S S Korsakova. 1992;92(1):56-60.

4. Domzal T, et al. Cavinton in the treatment of ischemic cerebral stroke. Clinical and computerized-tomographic evaluation. Neurol Neurochir Pol. May1986;20(3):234-40.

5.  Kakihana M, et al. Protective effect of vinpocetine on experimental brain ischemia.Nippon Yakurigaku Zasshi. Sep1982;80(3):225-9.

6. Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc. 1987 May;35(5):425-30.

7. Santos MS, Duarte AI, Moreira PI, et al. Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic Res. 2000 Jan;32(1):57-66.

8. Pereira C, Agostinho P, Oliveira CR. Vinpocetine attenuates the metabolic dysfunction induced by amyloid beta-peptides in PC12 cells. Free Radic Res. 2000 Nov;33(5):497-506.

9. Gaal L, Molnar P. Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus. Eur J Pharmacol. 1990 Oct 23;187(3):537-9.

10. Parnetti et al., Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech Ageing Dev. 2001 Nov;122(16):2025-40.

11. Matthews RT, Yang L, Browne S, et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8892-7.

12. Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid. Pharmacol Res. Sep1999;40(3):211-25.

13. Gamoh S, Hashimoto M, Sugioka K, et al. Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience. 1999;93(1):237-41.

14. Deijen JB, van der Beek EJ, Orlebeke JF, et al. Vitamin B-6 supplementation in elderly men: effects on mood, memory, performance and mental effort. Psychopharmacology (Berl). 1992;109(4):489-96.

15. Carmel R. Subtle cobalamin deficiency. Ann Intern Med. 1996 Feb 1;124(3):338-40.

16. Cunha UG, et al. Vitamin B12 deficiency and dementia. Int Psychogeriatr. Apr1995;7(1):85-8.

17. Masaki KH. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology. Mar2000;54(6):1265-72.

18. Paleologos M, et al. Cohort study of vitamin C intake and cognitive impairment. Am J Epidemiol. Jul1998;148(1):45-50.

19. Perrig WJ, et al. The relation between antioxidants and memory performance in the old and very old J Am Geriatr Soc. Jun1997;45(6):718-24.

20. Grundman M, et al. Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr. Feb2000;71(2):630S-636S.

21. Liu J, Head E, Gharib AM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2356-61.

22.  Acetyl-L-carnitine. Altern Med Rev. Dec1999;4(6):438-41.

23. Carta A, et al. Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere. Ann N Y Acad Sci. Sep1993;695:324-6.

24.  Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction Altern Med Rev. Jun1999;4(3):144-61.

25. Cenacchi T, et al. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milano). Apr1993;5(2):123-33.

26. Crook T, et al. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull. 1992;28(1):61-6.

27. Kleijnen J, et al. Ginkgo biloba for Cerebral Insufficiency. Br J Clin Pharm. 1992;34:352-58.

28. Maurer K, et al. Clinical Efficacy of Ginkgo biloba Special Extract EGb 761 in Dementia of the Alzheimer Type. J Psychiatr Res. 1997;31(6):645-55.

29.  Kose L, et al. Lipoperoxidation Induced by Hydrogen Peroxide in Human Erythrocyte Membranes. 2. Comparison of the Antioxidant Effect of Ginkgo biloba Extract (EGb 761) with Those of Water-soluble and Lipid-soluble Antioxidants. J Intern Med Res. 1995;23:9-18.

30. Auguet M, et al. Effects of Ginkgo biloba on Arterial Smooth Muscle Responses to Vasoactive Stimuli. Gen Pharmacol. 1982;13(2):169-71.

31.  Bauer U. 6-Month Double-blind Randomised Clinical Trial of Ginkgo biloba Extract Versus Placebo in Two Parallel Groups in Patients Suffering from Peripheral Arterial Insufficiency. Arzneim-Forsch/Drug Res. 1984;34(6):716-20.

32. Ramassamy C, et al. The Ginkgo biloba Extract, EGb761, Increases Synaptosomal Uptake of 5-hydroxytryptamine: In-vitro and Ex-vivo Studies. J Pharm Pharmacology. 1992;44(11):943-45.

33. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000 Jul;1(1):25-58.

34. Merck Manual eds, The Merck Manual of Diagnosis and Therapy, 15th edtion, Rahway, NJ: Merck & Co., Inc, 1997.

35. Life Extension eds., Disease Prevention and Treatment, 4th ed. Florida: Life Extension Media, 2003.

Return to Cognitive Function Introduction